Portal Vein Thrombosis in Cirrhosis

Overview

Journal J Clin Exp Hepatol

Publisher Elsevier

Specialty Gastroenterology

Date 2022 Jun 9

PMID 35677518

Authors

Akash Shukla

Suprabhat Giri

Affiliations

Soon will be listed here.

Abstract

Patients with cirrhosis of the liver are at high risk of developing portal vein thrombosis (PVT), which has a complex, multifactorial cause. The condition may present with a myriad of symptoms and can occasionally cause severe complications. Contrast-enhanced computed tomography (CT) is the gold standard for the diagnosis of PVT. There are uncertainties regarding the effect on PVT and its treatment outcome in patients with cirrhosis. The main challenge for managing PVT in cirrhosis is analyzing the risk of hemorrhage compared to the risk of thrombus extension leading to complications. All current knowledge regarding non-tumor PVT in cirrhosis, including epidemiology, risk factors, classification, clinical presentation, diagnosis, impact on natural history, and treatment, is discussed in the present article.

Citing Articles

Portal vein thrombosis in a patient on semaglutide.

Farooqi M, Khan M, Muhammad A, Agha A Qatar Med J. 2025; 2024(4):75.

PMID: 39925824 PMC: 11806721. DOI: 10.5339/qmj.2024.75.

The Imbalance of Homeostasis in Neutrophil Extracellular Traps is Associated with Portal Vein Thrombosis in Patients with Decompensated Cirrhosis.

Han M, Liu Y, Cao Y, Zhang Y, Yan Y, Deng S J Clin Transl Hepatol. 2024; 12(12):1009-1019.

PMID: 39649033 PMC: 11622206. DOI: 10.14218/JCTH.2024.00165.

Enhancement of endothelial function and attenuation of portal vein injury using mesenchymal stem cells carrying miRNA-25-3p.

Nie G, Zhang H, Luo W, Zhu X, Xie D, Yan J Sci Rep. 2024; 14(1):15113.

PMID: 38956421 PMC: 11220092. DOI: 10.1038/s41598-024-64263-6.

Porto-sinusoidal Vascular Disease: Classification and Clinical Relevance.

Premkumar M, Anand A J Clin Exp Hepatol. 2024; 14(5):101396.

PMID: 38601747 PMC: 11001647. DOI: 10.1016/j.jceh.2024.101396.

Role of contrast-enhanced ultrasound for differentiation of benign vs. malignant portal vein thrombosis in hepatocellular carcinoma - A systematic review a meta-analysis.

Giri S, Vaidya A, Agrawal D, Varghese J, Patel R, Tripathy T Australas J Ultrasound Med. 2024; 27(1):56-64.

PMID: 38434544 PMC: 10902826. DOI: 10.1002/ajum.12375.

References

Pettinari I, Vukotic R, Stefanescu H, Pecorelli A, Morelli M, Grigoras C . Clinical Impact and Safety of Anticoagulants for Portal Vein Thrombosis in Cirrhosis. Am J Gastroenterol. 2018; 114(2):258-266. DOI: 10.1038/s41395-018-0421-0. View

Turnes J, Garcia-Pagan J, Gonzalez M, Aracil C, Calleja J, Ripoll C . Portal hypertension-related complications after acute portal vein thrombosis: impact of early anticoagulation. Clin Gastroenterol Hepatol. 2008; 6(12):1412-7. DOI: 10.1016/j.cgh.2008.07.031. View

Bagheri Lankarani K, Homayon K, Motevalli D, Heidari S, Alavian S, Malek-Hosseini S . Risk Factors for Portal Vein Thrombosis in Patients With Cirrhosis Awaiting Liver Transplantation in Shiraz, Iran. Hepat Mon. 2016; 15(12):e26407. PMC: 4779252. DOI: 10.5812/hepatmon.26407. View

Stine J, Shah N, Argo C, Pelletier S, Caldwell S, Northup P . Increased risk of portal vein thrombosis in patients with cirrhosis due to nonalcoholic steatohepatitis. Liver Transpl. 2015; 21(8):1016-21. PMC: 6615024. DOI: 10.1002/lt.24134. View

Tublin M, Dodd 3rd G, BARON R . Benign and malignant portal vein thrombosis: differentiation by CT characteristics. AJR Am J Roentgenol. 1997; 168(3):719-23. DOI: 10.2214/ajr.168.3.9057522. View

Ayala R, Rapado I, Grande S, Moreno E, Martinez-Lopez J . JAK2 exon 12 mutations were not found in liver transplant recipients with or without pretransplant portal vein thrombosis. Eur J Gastroenterol Hepatol. 2014; 26(3):362-3. DOI: 10.1097/MEG.0000000000000022. View

Qi X, De Stefano V, Li H, Dai J, Guo X, Fan D . Anticoagulation for the treatment of portal vein thrombosis in liver cirrhosis: a systematic review and meta-analysis of observational studies. Eur J Intern Med. 2015; 26(1):23-9. DOI: 10.1016/j.ejim.2014.12.002. View

Senzolo M, Riva N, Dentali F, Rodriguez-Castro K, Sartori M, Bang S . Long-Term Outcome of Splanchnic Vein Thrombosis in Cirrhosis. Clin Transl Gastroenterol. 2018; 9(8):176. PMC: 6092393. DOI: 10.1038/s41424-018-0043-2. View

Gerwing M, Wilms C, Heinzow H, Sporns P, Heindel W, Schmidt H . Escalating interventional recanalization therapy in non-cirrhotic, non-malignant acute portal vein thrombosis. Eur J Gastroenterol Hepatol. 2019; 31(12):1584-1591. DOI: 10.1097/MEG.0000000000001559. View

10.

Sarin S, Choudhury A, Sharma M, Maiwall R, Al Mahtab M, Rahman S . Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific association for the study of the liver (APASL): an update. Hepatol Int. 2019; 13(4):353-390. PMC: 6728300. DOI: 10.1007/s12072-019-09946-3. View

11.

Feltracco P, Barbieri S, Cillo U, Zanus G, Senzolo M, Ori C . Perioperative thrombotic complications in liver transplantation. World J Gastroenterol. 2015; 21(26):8004-13. PMC: 4499342. DOI: 10.3748/wjg.v21.i26.8004. View

12.

Amitrano L, Guardascione M, Menchise A, Martino R, Scaglione M, Giovine S . Safety and efficacy of anticoagulation therapy with low molecular weight heparin for portal vein thrombosis in patients with liver cirrhosis. J Clin Gastroenterol. 2009; 44(6):448-51. DOI: 10.1097/MCG.0b013e3181b3ab44. View

13.

Ponziani F, Zocco M, Garcovich M, DAversa F, Roccarina D, Gasbarrini A . What we should know about portal vein thrombosis in cirrhotic patients: a changing perspective. World J Gastroenterol. 2012; 18(36):5014-20. PMC: 3460326. DOI: 10.3748/wjg.v18.i36.5014. View

14.

Malkowski P, Pawlak J, Michalowicz B, Szczerban J, Wroblewski T, Leowska E . Thrombolytic treatment of portal thrombosis. Hepatogastroenterology. 2003; 50(54):2098-100. View

15.

Iwakiri Y . Endothelial dysfunction in the regulation of cirrhosis and portal hypertension. Liver Int. 2011; 32(2):199-213. PMC: 3676636. DOI: 10.1111/j.1478-3231.2011.02579.x. View

16.

Anand A, Saha A, Seth A, Chopra G, Nair V, Sharma V . Symptomatic portal system thrombosis in soldiers due to extended stay at extreme altitude. J Gastroenterol Hepatol. 2005; 20(5):777-83. DOI: 10.1111/j.1440-1746.2005.03723.x. View

17.

Tripodi A, Primignani M, Lemma L, Chantarangkul V, Mannucci P . Evidence that low protein C contributes to the procoagulant imbalance in cirrhosis. J Hepatol. 2013; 59(2):265-70. DOI: 10.1016/j.jhep.2013.03.036. View

18.

Xu X, Guo X, De Stefano V, Silva-Junior G, Goyal H, Bai Z . Nonselective beta-blockers and development of portal vein thrombosis in liver cirrhosis: a systematic review and meta-analysis. Hepatol Int. 2019; 13(4):468-481. DOI: 10.1007/s12072-019-09951-6. View

19.

Sherman C, Behr S, Dodge J, Roberts J, Yao F, Mehta N . Distinguishing Tumor From Bland Portal Vein Thrombus in Liver Transplant Candidates With Hepatocellular Carcinoma: the A-VENA Criteria. Liver Transpl. 2018; 25(2):207-216. PMC: 7103424. DOI: 10.1002/lt.25345. View

20.

Intagliata N, Henry Z, Maitland H, Shah N, Argo C, Northup P . Direct Oral Anticoagulants in Cirrhosis Patients Pose Similar Risks of Bleeding When Compared to Traditional Anticoagulation. Dig Dis Sci. 2016; 61(6):1721-7. DOI: 10.1007/s10620-015-4012-2. View